Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy

Targeted Oncology

Volumn 11, Issue 4, 2016, Pages 549-552

  Bondon Guitton, E ^a   Combret, S ^b   Perault Pochat M C ^c   Steve Dumont M ^d   Bagheri, H ^a   Huguet, F ^e   Despas, F ^a   Pathak, A ^a   Montastruc, J L ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d University of Côte d'Azur   (France)

^e Institut Universitaire du Cancer   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; PYRIMIDINE DERIVATIVE;

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DATA BASE; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; RISK FACTOR;

ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; PYRIMIDINES; RISK FACTORS;

EID: 84958774617     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-016-0417-x     Document Type: Article

References (15)

1. Aichberger KJ, Herndlhofer S, Schernthaner G-H, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533–9.
2. Le Coutre P, Rea D, Abruzzese E, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011;103:1347–8.
3. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12:337–40.
4. Levato L, Cantaffa R, Kropp MG, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol. 2013;90:531–2.
5. Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27:1316–21.
6. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27:1310–5.
7. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86:610–1.
8. Spreux A, Baldin B, Chichmanian RM. Pharmacovigilance in practice. Transfus Clin Biol. 1999;6:254–9.
9. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109–17.
10. Begaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie. 1985;40:111–8.
11. Montastruc J-L, Sommet A, Lacroix I, et al. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine. 2006;73:629–32.
12. Valent P, Hadzijusufovic E, Schernthaner G-H, et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2015;125:901–6.
13. Ouriel K. Peripheral arterial disease. Lancet. 2001;358:1257–64.
14. Vray M, Chwalow J, Charansonney O, et al. National study of obliterative arterial disease of the lower limbs involving general practitioners in France: Artemio study. J Cardiovasc Pharmacol. 1995;25 Suppl 2:S51–7.
15. Rix U, Hantschel O, Dürnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110:4055–63.